Table 1.
Patient characteristics by treatment allocation in the TOGETHER trial
| Fluvoxamine (n=741) | Placebo (n=756) | |
|---|---|---|
| Sex | ||
| Female | 409 (55%) | 453 (60%) |
| Male | 332 (45%) | 303 (40%) |
| Race | ||
| Mixed race* | 709 (96%) | 719 (95%) |
| White | 6 (1%) | 6 (1%) |
| Black or African American | 5 (1%) | 5 (1%) |
| Unknown | 21 (3%) | 26 (3%) |
| Age, years | ||
| <50 | 379 (51%) | 368 (49%) |
| ≥50 | 327 (44%) | 328 (43%) |
| Unspecified | 46 (6%) | 49 (6%) |
| Age descriptive statistics | ||
| Median (IQR) | 50 (39–56) | 49 (38–56) |
| Body-mass index | ||
| <30 kg/m2 | 355 (48%) | 373 (49%) |
| ≥30 kg/m2 | 376 (51%) | 375 (50%) |
| Unspecified | 10 (1%) | 8 (1%) |
| Time since onset of symptoms, days | ||
| 0–3 | 328 (44%) | 310 (41%) |
| 4–7 | 239 (32%) | 267 (35%) |
| Unspecified | 174 (23%) | 179 (24%) |
| Risk factors | ||
| Chronic cardiac disease | 9 (1%) | 7 (1%) |
| Uncontrolled hypertension | 106 (14%) | 88 (12%) |
| Chronic pulmonary disease | 6 (1%) | 3 (<1%) |
| Asthma | 12 (2%) | 16 (2%) |
| Chronic kidney disease | 2 (<1%) | 2 (<1%) |
| Rheumatological disorder | 1 (<1%) | 0 |
| Chronic neurological disorder | 8 (1%) | 6 (1%) |
| Type 1 diabetes | 25 (3%) | 22 (3%) |
| Type 2 diabetes | 104 (14%) | 92 (12%) |
| Autoimmune disease | 0 | 2 (<1%) |
| Any other risk factor(s) or comorbidities | 25 (3%) | 24 (3%) |
Data are n (%).
*
Self-identified as someone with mixed ancestry.